New genetic added to the Graff Breeding family - Qdula®
New Bee and Butterfly Friendly, Mosquito Repellent Lavender from Graff Breeding
At Graff Breeding A/S we trust in our ability to be continuously inspired by nature and its shapes, colors and unique possibilities. That is why, we for more than 30 years have bred Hibiscus, last years have added Poinsettia and Dipladenia / Mandevilla, to bring forth natures many jewels for our customers and their consumers home and gardens around the world.
The latest product that have inspired us and our breeding work is Lavender, and we are happy to announce, the introduction of our first Lavandula Stoechas (French Lavender); Q-dula® Purple Eternity.
Q-dula® Purple Eternity has been selected for commercial trial among thousands of interesting Stoechas due to:
Uniformity and plant health
Continuously flowering / re-blooming
Consumer / garden value
Transport capability
Strong up-right growth
Suitable for pot 9 cm. and up
Suitable for Patio Combinations
Q-dula® is the tradename for our new Lavender breeding line and match our other lines of genetics like HibisQs®, Q-deville® and Q-ismas Star®. We have decided to work with flower brands, where we use the letter “Q” in all our genetic lines, due to;
“Q” reflects Quality and uniQue products
The letter “Q” is often used as an alternative to the female sign ♀
“Q” gives a red line through our breeding, which we call Q-genetic
Q-dula® Purple Eternity is reblooming again and again after +/- 3 weeks, why it gives the end consumers high Patio or Garden value / performance. Furthermore, the habit makes it very interesting for combinations, eventually with Mandevilla, Hibiscus or other major Patio plants.
Q-dula® Purple Eternity QL1 has been commercially tested in both South and North-Europa. Here it has proved its uniformity, plant health, upright growth, and capability for modern production methods in smaller pots – and outdoor production in larger containers.
Availability
Q-dula® Purple Eternity (QL1) cuttings are available for commercial trial production delivery from January 1 2021.